Smith Stan

SEC source: 0001878313-26-000099 · form4.xml · derivative · entry 1

Smith Stan · CIK 0001913199 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 38,871

Underlying: Common Stock · 38,871 shares

Expires 2036-09-30

F1 · derivative.exercise_date: The stock options, granted on September 30, 2026 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.

F2 · ownership.direct: These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

SEC source: 0001878313-26-000070 · form4.xml · derivative · entry 1

Smith Stan · CIK 0001913199 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 32,003

Underlying: Common Stock · 32,003 shares

Expires 2036-06-30

F1 · derivative.exercise_date: The stock options, granted on June 30, 2026 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.

F2 · ownership.nature: These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

SEC source: 0001878313-26-000061 · form4.xml · nonDerivative · entry 1

Smith Stan · CIK 0001913199 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 1,519,178

F1 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.32 to $1.40, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, to any security holder of the issuer, or to the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.

F2 · ownership.nature: These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

SEC source: 0001878313-26-000029 · form4.xml · derivative · entry 1

Smith Stan · CIK 0001913199 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 33,099

Underlying: Common Stock · 33,099 shares

Expires 2036-03-31

F1 · derivative.exercise_date: The stock options, granted on March 31, 2026 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.

F2 · ownership.direct: These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

SEC source: 0001878313-26-000016 · form4.xml · derivative · entry 1

Smith Stan · CIK 0001913199 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 29,216

Underlying: Common Stock · 29,216 shares

Expires 2035-12-31

F1 · derivative.exercise_date: The stock options, granted on December 31, 2025 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.

F2 · ownership.direct: These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

SEC source: 0001878313-25-000073 · form4.xml · derivative · entry 5

Smith Stan · CIK 0001913199 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 57,189

Underlying: Common Stock · 57,189 shares

Expires 2028-12-22

F6 · shares: These warrants were purchased pursuant to a Securities Purchase Agreement and were deemed options under the Issuer's 2021 Equity Incentive Plan on December 22, 2025. The options are exercisable beginning on the sixth month anniversary of the issuance date and expire 3-years after the initial issuance date.

F7 · ownership.nature: These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

SEC source: 0001878313-25-000073 · form4.xml · nonDerivative · entry 1

Smith Stan · CIK 0001913199 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 1,421,478

F1 · shares: The common stock was purchased pursuant to a Securities Purchase Agreement and were issued under the Issuer's 2021 Equity Incentive Plan on December 22, 2025.

F2 · ownership.nature: These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

SEC source: 0001878313-25-000063 · form4.xml · nonDerivative · entry 3

Smith Stan · CIK 0001913199 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 4,580

F3 · ownership.nature: These securities are beneficially owned by Mr. Smith through the Blake Sarai Teitei Smith IL Unif Trns Min Act. They are beneficially owned by Mr. Smith's family member. The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

SEC source: 0001878313-25-000063 · form4.xml · nonDerivative · entry 2

Smith Stan · CIK 0001913199 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 4,580

F2 · ownership.nature: These securities are beneficially owned by Mr. Smith through the Gage Quentin Smith IL Unif Trns Min Act. They are beneficially owned by Mr. Smith's family member. The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

SEC source: 0001878313-25-000063 · form4.xml · nonDerivative · entry 1

Smith Stan · CIK 0001913199 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 4,580

F1 · ownership.nature: These securities are beneficially owned by Mr. Smith through the Travis Deo Zai Zai Smith IL Unif Trns Min Act. They are beneficially owned by Mr. Smith's family member. The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

SEC source: 0001878313-25-000052 · form4.xml · nonDerivative · entry 1

Smith Stan · CIK 0001913199 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 1,364,289

F1 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.03 to $1.051, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, to any security holder of the issuer, or to the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.

F2 · ownership.nature: These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

SEC source: 0001878313-25-000045 · form4.xml · nonDerivative · entry 2

Smith Stan · CIK 0001913199 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 1,349,289

F3 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.9550 to $1.05, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, to any security holder of the issuer, or to the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.

F2 · ownership.nature: These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

SEC source: 0001878313-25-000045 · form4.xml · nonDerivative · entry 1

Smith Stan · CIK 0001913199 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 1,334,289

F1 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.9675 to $0.9899, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, to any security holder of the issuer, or to the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.

F2 · ownership.nature: These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

SEC source: 0001878313-25-000037 · form4.xml · derivative · entry 1

Smith Stan · CIK 0001913199 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 24,844

Underlying: Common Stock · 24,844 shares

Expires 2035-10-02

F1 · derivative.exercise_date: The stock options, granted on October 2, 2025, pursuant to the MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.

F2 · ownership.direct: These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

SEC source: 0001878313-25-000019 · form4.xml · derivative · entry 2

Smith Stan · CIK 0001913199 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 19,230

Underlying: Common Stock · 19,230 shares

Expires 2028-10-01

F3 · shares: These warrants were purchased pursuant to a Securities Purchase Agreement and were deemed options under the Issuer's 2021 Equity Incentive Plan on October 1, 2025. The options are exercisable beginning on the six-month anniversary of the issuance date and expire 3-years after the initial issuance date.

F4 · ownership.nature: These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

SEC source: 0001878313-25-000019 · form4.xml · nonDerivative · entry 1

Smith Stan · CIK 0001913199 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 1,324,289

F1 · shares: The common stock was purchased pursuant to a Securities Purchase Agreement and were issued under the Issuer's 2021 Equity Incentive Plan on October 1, 2025

F2 · ownership.nature: These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

SEC source: 0001127602-25-018653 · form4.xml · derivative · entry 1

Smith Stan · CIK 0001913199 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 24,747

Underlying: Common Stock · 24,747 shares

Expires 2035-06-30

F1 · derivative.exercise_date: The stock options, granted on June 30, 2025 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.

F2 · ownership.direct: These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

SEC source: 0001127602-25-016869 · form4.xml · derivative · entry 2

Smith Stan · CIK 0001913199 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 33,333

Underlying: Common Stock · 33,333 shares

Expires 2030-06-03

F3 · shares: These warrants were purchased pursuant to a Securities Purchase Agreement and were deemed options under the Issuer's 2021 Equity Incentive Plan on June 3, 2025. The options are exercisable beginning on the six-month anniversary of the issuance date and expire 5-years after the initial issuance date.

F4 · ownership.nature: These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust dated 1993.

SEC source: 0001127602-25-016869 · form4.xml · nonDerivative · entry 1

Smith Stan · CIK 0001913199 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 1,305,059

F1 · shares: The common stock was purchased pursuant to a Securities Purchase Agreement and were issued under the Issuer's 2021 Equity Incentive Plan on June 3, 2025.

F2 · ownership.nature: These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

SEC source: 0001127602-25-013963 · form4.xml · derivative · entry 2

Smith Stan · CIK 0001913199 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 66,666

Underlying: Common Stock · 66,666 shares

Expires 2031-05-08

F3 · shares: These warrants were purchased pursuant to a Securities Purchase Agreement and were deemed options under the Issuer's 2021 Equity Incentive Plan on May 8, 2025. The options are exercisable beginning on the one-year anniversary of the issuance date and expire 6-years after the initial issuance date.

F4 · ownership.nature: These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

SEC source: 0001127602-25-013963 · form4.xml · nonDerivative · entry 1

Smith Stan · CIK 0001913199 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 1,271,726

F1 · shares: The common stock was purchased pursuant to a Securities Purchase Agreement and were issued under the Issuer's 2021 Equity Incentive Plan on March 8, 2025.

F2 · ownership.nature: These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

SEC source: 0001127602-25-011819 · form4.xml · derivative · entry 1

Smith Stan · CIK 0001913199 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 24,800

Underlying: Common Stock · 24,800 shares

Expires 2035-04-04

F1 · derivative.exercise_date: The stock options, granted on April 4, 2025 pursuant to MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.

F2 · ownership.nature: These securities are benefically owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

SEC source: 0001127602-25-008327 · form4.xml · derivative · entry 2

Smith Stan · CIK 0001913199 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2031-03-03

F3 · shares: These warrants were purchased pursuant to a Securities Purchase Agreement and were deemed options under the Issuer's 2021 Equity Incentive Plan on March 3, 2025. The options are exercisable beginning on the one-year anniversary of the issuance date and expire 6-years after the initial issuance date.

F4 · ownership.nature: These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

SEC source: 0001127602-25-008327 · form4.xml · nonDerivative · entry 1

Smith Stan · CIK 0001913199 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 1,205,060

F1 · shares: The common stock was purchased pursuant to a Securities Purchase Agreement and were issued under the Issuer's 2021 Equity Incentive Plan on March 3, 2025.

F2 · ownership.nature: These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

SEC source: 0001127602-25-006574 · form4.xml · derivative · entry 2

Smith Stan · CIK 0001913199 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2030-08-24

F3 · derivative.exercise_date: These warrants were purchased pursuant to a Securities Purchase Agreement and were deemed options under the Issuer's 2021 Equity Incentive Plan on February 24, 2024. The options are exercisable beginning on the six month anniversary of the issuance date and expire 5-years after the initial exercise date.

F4 · ownership.nature: These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

SEC source: 0001127602-25-006574 · form4.xml · nonDerivative · entry 1

Smith Stan · CIK 0001913199 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 1,180,060

F1 · shares: The common stock was purchased pursuant to a Securities Purchase Agreement and were issued under the Issuer's 2021 Equity Incentive Plan on February 24, 2024.

F2 · ownership.nature: These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

SEC source: 0001127602-25-008322 · form4a.xml · derivative · entry 2

Smith Stan · CIK 0001913199 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2031-02-24

F3 · security: This Form 4/A is being filed to correct the "Date Exercisable" and "Expiration Date" in Section 6 of Table II reported in the original Form 4 filed on February 25, 2025 as well as to correct the date of the Securities Purchase Agreement orginally referenced in the footnote 1 and 3 to "February 24, 2025".

F4 · shares: These warrants were purchased pursuant to a Securities Purchase Agreement and were deemed options under the Issuer's 2021 Equity Incentive Plan on February 24, 2025. The options are exercisable beginning on the one-year anniversary of the issuance date and expire 6-years after the inital issuance date.

F5 · ownership.nature: These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

SEC source: 0001127602-25-008322 · form4a.xml · nonDerivative · entry 1

Smith Stan · CIK 0001913199 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 1,180,060

F1 · shares: The common stock was purchased pursuant to a Securities Purchase Agreement and were issued under the Issuer's 2021 Equity Incentive Plan on February 24, 2025.

F2 · ownership.nature: These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

SEC source: 0001127602-25-000391 · form4.xml · derivative · entry 1

Smith Stan · CIK 0001913199 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 12,782

Underlying: Common Stock · 12,782 shares

Expires 2034-12-31

F1 · derivative.exercise_date: The stock options, granted on December 31, 2024 pursuant to MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.

F2 · ownership.nature: These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

SEC source: 0001127602-24-029383 · form4.xml · derivative · entry 2

Smith Stan · CIK 0001913199 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2030-06-13

F3 · derivative.exercise_date: These warrants were purchased pursuant to a Securities Purchase Agreement and were deemed options issued under the Issuer's 2021 Equity Incentive Plan on December 13, 2024. The options are exercisable beginning on the six month anniversary of the issuance date and expire 5-years after the initial exercise date.

F4 · ownership.nature: These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

SEC source: 0001127602-24-029383 · form4.xml · nonDerivative · entry 1

Smith Stan · CIK 0001913199 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 1,130,060

F1 · shares: The common stock was purchased pursuant to a Securities Purchase Agreement and were issued under the Issuer's 2021 Equity Incentive Plan on December 13, 2024.

F2 · ownership.nature: These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

SEC source: 0001127602-24-026376 · form4.xml · derivative · entry 2

Smith Stan · CIK 0001913199 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2030-05-01

F3 · derivative.exercise_date: These warrants were purchased pursuant to a Securities Purchase Agreement and were deemed options issued under the Issuer's 2021 Equity Incentive Plan on November 1, 2024. The options are exercisable beginning on the six month anniversary of the issuance date and expire 5-years after the initial exercise date.

F4 · ownership.nature: These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

SEC source: 0001127602-24-026376 · form4.xml · nonDerivative · entry 1

Smith Stan · CIK 0001913199 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 957,568

F1 · shares: The common stock was purchased pursuant to a Securities Purchase Agreement and were issued under the Issuer's 2021 Equity Incentive Plan on November 1, 2024.

F2 · ownership.nature: These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

SEC source: 0001127602-24-024953 · form4.xml · derivative · entry 1

Smith Stan · CIK 0001913199 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 9,040

Underlying: Common Stock · 9,040 shares

Expires 2034-09-30

F1 · derivative.exercise_date: The stock options, granted on September 30, 2024 pursuant to MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of thate date.

F2 · ownership.nature: These securities are benefically owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

SEC source: 0001127602-24-019872 · form4.xml · derivative · entry 1

Smith Stan · CIK 0001913199 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 7,160

Underlying: Common Stock · 7,160 shares

Expires 2034-06-30

F1 · derivative.exercise_date: The stock options, granted on June 30, 2024 pursuant to MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.

F2 · ownership.nature: These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

SEC source: 0001878313-26-000021 · form4.xml · nonDerivative · entry 2

Smith Stan · CIK 0001913199 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 1,444,178

F2 · shares: These securities were beneficially owned by Mr. Smith through the Stan V Smith CUST Gage Quentin Smith IL UNIF TRNS MIN Act account. On May 1, 2024, the shares were transferred to The Stan V. Smith Trust Dated 1993.

F1 · ownership.nature: These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

SEC source: 0001127602-24-013488 · form4.xml · derivative · entry 2

Smith Stan · CIK 0001913199 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 147,492

Underlying: Common Stock · 147,492 shares

Expires 2029-10-25

F3 · derivative.exercise_date: The warrants were purchased pursuant to a Securities Purchase Agreement dated April 22, 2024 and were deemed options issued under the Issuer's 2021 Equity Inventive Plan on April 25, 2024. The options are exercisable beginning on the six month anniversary of the issuance date and expire 5-years after the initial exercise date.

F4 · ownership.nature: These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

SEC source: 0001127602-24-013488 · form4.xml · nonDerivative · entry 1

Smith Stan · CIK 0001913199 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 1,005,060

F1 · shares: The common stock was purchased pursuant to a Securities Purchase Agreement dated April 22, 2024 and were issued under the Issuer's 2021 Equity Incentive Plan on April 25, 2024.

F2 · ownership.nature: These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

SEC source: 0001127602-24-011901 · form4.xml · derivative · entry 1

Smith Stan · CIK 0001913199 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 11,491

Underlying: Common Stock · 11,491 shares

Expires 2034-03-31

F1 · derivative.exercise_date: The stock options, granted on March 31, 2024 pursuant to MAIA Biotechnlogy, Inc.'s 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.

F2 · ownership.nature: These securities are beneficailly owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

SEC source: 0001127602-24-010327 · form4.xml · derivative · entry 2

Smith Stan · CIK 0001913199 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 170,940

Underlying: Common Stock · 170,940 shares

Expires 2029-09-14

F3 · derivative.exercise_date: The warrants were purchased pursuant to a Securities Purchase Agreement dated March 11, 2024 and were deemed options issued under the Issuer's 2021 Equity Incentive Plan on March 14, 2024. The options are exercisable beginning on the six month anniverary of the issuance date and expire 5-years after the initial exercise date.

F4 · ownership.nature: These securities are beneficailly owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

SEC source: 0001127602-24-010327 · form4.xml · nonDerivative · entry 1

Smith Stan · CIK 0001913199 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 857,568

F1 · shares: The common stock was purchased pursuant to a Securities Purchase Agreement dated March 11, 2024 and were issued under the Issuer's 2021 Equity Incentive Plan on March 14, 2024.

F2 · ownership.nature: These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

SEC source: 0001127602-24-000654 · form4.xml · derivative · entry 1

Smith Stan · CIK 0001913199 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 19,273

Underlying: Common Stock · 19,273 shares

Expires 2033-12-31

F1 · derivative.exercise_date: The stock options, granted on December 31, 2023 pursuant to MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.

F2 · ownership.nature: These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

SEC source: 0001127602-23-025141 · form4.xml · derivative · entry 1

Smith Stan · CIK 0001913199 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 10,472

Underlying: Common Stock · 10,472 shares

Expires 2033-09-30

F1 · derivative.exercise_date: The stock options, granted on September 30, 2023 pursuant to MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.

F2 · ownership.nature: These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

SEC source: 0001127602-23-019766 · form4.xml · derivative · entry 1

Smith Stan · CIK 0001913199 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 11,138

Underlying: Common Stock · 11,138 shares

Expires 2033-06-30

F1 · derivative.exercise_date: The stock options, granted on June 30, 2023 pursuant to MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.

F2 · ownership.nature: These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

SEC source: 0001127602-23-013708 · form4.xml · nonDerivative · entry 1

Smith Stan · CIK 0001913199 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 686,628

F1 · kind: These shares were purchased by the reporting person in the issuer's follow-on offering, which closed on April 27, 2023.

F2 · ownership.nature: These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

SEC source: 0001127602-23-013327 · form4.xml · nonDerivative · entry 1

Smith Stan · CIK 0001913199 · Director

10b5-1 filing: Plan reported

Ownership: Indirect · See Footnote

Disclosed balance after: 553,328

F1 · price: The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan of The Stan V. Smith Trust Dated 1993 that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

F2 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $3.50 to $3.95, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, to any security holder of the Issuer, or to the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.

F1 · ownership.nature: The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan of The Stan V. Smith Trust Dated 1993 that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

SEC source: 0001127602-23-012021 · form4.xml · derivative · entry 1

Smith Stan · CIK 0001913199 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · see footnote

Disclosed balance after: 7,094

Underlying: Common Stock · 7,094 shares

Expires 2033-03-31

F1 · derivative.exercise_date: The stock options, granted on March 31, 2023 pursuant to MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.

F2 · ownership.nature: These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

SEC source: 0001127602-23-011434 · form4.xml · nonDerivative · entry 1

Smith Stan · CIK 0001913199 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 543,328

F1 · price: The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan of The Stan V. Smith Trust Dated 1993 that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

F2 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $3.26 to $3.60, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, to any security holder of the Issuer, or to the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.

F1 · ownership.nature: The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan of The Stan V. Smith Trust Dated 1993 that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

SEC source: 0001127602-23-011265 · form4.xml · nonDerivative · entry 2

Smith Stan · CIK 0001913199 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 542,390

F1 · price: The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan of The Stan V. Smith Trust Dated 1993 that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

F3 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $3.11 to $3.51, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, to any security holder of the Issuer, or to the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.

F1 · ownership.nature: The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan of The Stan V. Smith Trust Dated 1993 that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

SEC source: 0001127602-23-011265 · form4.xml · nonDerivative · entry 1

Smith Stan · CIK 0001913199 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 540,528

F1 · price: The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan of The Stan V. Smith Trust Dated 1993 that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

F2 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $3.07 to $3.39, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, to any security holder of the Issuer, or to the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.

F1 · ownership.nature: The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan of The Stan V. Smith Trust Dated 1993 that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.